StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.02−0.08 (-1.13%)

Close on Nov 17, 2026Market cap $254.77MP/E –Yield –

Evommune revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Evommune's revenue for the twelve months ending Sep 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was $13.00M, up 85.7% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.00M+85.7%
FY2024Dec 31, 2024$7.00M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$0-100.0%
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$10.00M–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$3.00M–
Q4 FY2024Dec 31, 2024$0–

More Evommune figures

See a number that looks wrong?